Blood and Marrow Transplant Clinic

Fanconi Anemia

World-renowned experts from University of Minnesota Physicians are leading the way in treating Fanconi anemia (FA) patients with blood and marrow transplantation (BMT) through translational research and clinical care. Fanconi anemia is a rare, genetic blood disorder discovered primarily during childhood that prevents bone marrow from producing enough new blood cells, causing bone marrow failure and serious health problems such as cancer. The Fanconi Anemia Comprehensive Care Program (FACCP) at University of Minnesota Amplatz Children’s Hospital and University of Minnesota Medical Center, Fairview is the largest treatment center worldwide and home of the world’s first umbilical cord blood transplant for a FA patient using preimplantation genetic testing, ensuring a perfect tissue match.

DISTINGUISHING FACTS

  • Performed sibling donor transplants since 1976 and unrelated donor transplants since 1987 for FA
  • Treated more than 200 FA adults and children with BMT with greater than 85% survival after an unrelated donor transplant and 100% survival in those children treated with a matched sibling donor
  • Lowered the dose of radiation given to unrelated transplant recipients to reduce the risk of early and late effects, with marked success
  • Completely eliminated radiation in patients with sibling donors
  • Home of world’s first successful BMT using a matched sibling donor in 1968
  • Highly experienced, having performed more than 5,500 blood and marrow stem cell transplants as of 2010


 

ACADEMIC MEDICINE

  • Exploring novel ways to increase cure rates and improve quality of life for patients with FA
  • Leading the nation in several areas of FA research, translating that research into clinical practice
  • Opportunity for patients to participate in pioneering research studies and clinical trials
  • Committed to developing new treatments for FA using different kinds of stem cells — including endeavors that aim to determine which types of cells are most effective for FA, how we can prepare cells to deliver the missing protein, new delivery methods such as injection into wounds, and more
  • Actively involved in collaborating with researchers around the world in exploring new and safer ways to treat FA and improve the quality of life for those with the disease
     


 
 

Central Scheduling: 612.672.7422

Provider Referrals: 612.672.7000

Administrative Offices: 612.884.0600
 

©2014 Regents of the University of Minnesota. All rights reserved.